CelLBxHealth (FRA:DWV) Total Receivables: €0.19 Mil (As of Dec. 2025)


What is CelLBxHealth Total Receivables?

CelLBxHealth FRA:DWV Total Receivables is €0.19 Mil as of Dec. 2025. The stock has 5 warning signs investors should review.

CelLBxHealth's Total Receivables for the quarter that ended in Dec. 2025 was €0.19 Mil.

CelLBxHealth Total Receivables Historical Data

* Premium members only.

The historical data trend for CelLBxHealth's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CelLBxHealth Total Receivables Chart

CelLBxHealth Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.43 2.04 1.71 1.51 0.19

CelLBxHealth Semi-Annual Data
Apr16 Oct16 Apr17 Oct17 Apr18 Oct18 Apr19 Oct19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.71 2.27 1.51 1.98 0.19

CelLBxHealth Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of €0.19 Mil mean?
CelLBxHealth (FRA:DWV) has a Total Receivables of €0.19 Mil as of Dec. 2025. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on CelLBxHealth and its competitors.
Is CelLBxHealth's Total Receivables too high?
CelLBxHealth's current Total Receivables is €0.19 Mil.
How does CelLBxHealth's Total Receivables compare to TMO and DHR?
CelLBxHealth's Total Receivables of €0.19 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Medical Diagnostics & Research company?
A good Total Receivables depends on the Medical Diagnostics & Research industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on CelLBxHealth and its competitors. CelLBxHealth's current Total Receivables is €0.19 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CelLBxHealth stock overvalued right now?
CelLBxHealth (FRA:DWV) has a current Total Receivables of €0.19 Mil. The current Total Receivables is €0.19 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For CelLBxHealth (FRA:DWV), the current Total Receivables is €0.19 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CelLBxHealth Business Description

Other Exchanges ANPCF:USACLBX:UK
Address 10 Nugent Road, The Surrey Research Park, Surrey, Guildford, GBR, GU2 7AF
CelLBxHealth PLC is active in the healthcare sector in the United Kingdom. The Company's principal trading activity is undertaken in relation to the development and commercialization of the Parsortix cell separation system, with deployment in liquid biopsy that is non-invasive cancer diagnostics. It is a medical diagnostic company specializing in the development of pioneering products in cancer diagnostics. Its patented Parsortix technology can potentially treat and diagnose various forms of cancer. The Parsortix system can capture and harvest CTCs from patient blood. Its geographical segments include Europe and North America, of which the majority of its revenue is generated from Europe.